

# Howard L Kaufman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7722313/publications.pdf>

Version: 2024-02-01

159  
papers

14,611  
citations

57631

44  
h-index

24179

110  
g-index

164  
all docs

164  
docs citations

164  
times ranked

13247  
citing authors

| #  | ARTICLE                                                                                                                                                                                                                                                                  | IF   | CITATIONS |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 1  | Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 2780-2788.                                                                                                                   | 0.8  | 1,988     |
| 2  | Oncolytic viruses: a new class of immunotherapy drugs. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 642-662.                                                                                                                                                         | 21.5 | 1,055     |
| 3  | Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1374-1385.                                                                           | 5.1  | 1,034     |
| 4  | gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma. <i>New England Journal of Medicine</i> , 2011, 364, 2119-2127.                                                                                                                               | 13.9 | 809       |
| 5  | Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.                                                                                                                                                     |      | 610       |
| 6  | Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor-encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 5763-5771.                            | 0.8  | 540       |
| 7  | Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 1658-1667. | 0.8  | 483       |
| 8  | Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma. <i>Annals of Surgical Oncology</i> , 2010, 17, 718-730.                                                      | 0.7  | 451       |
| 9  | Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIb-IV Melanoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 2619-2626.                                                                                         | 0.8  | 449       |
| 10 | Integrating oncolytic viruses in combination cancer immunotherapy. <i>Nature Reviews Immunology</i> , 2018, 18, 498-513.                                                                                                                                                 | 10.6 | 448       |
| 11 | Characterization of CD4+CD25+ Regulatory T Cells in Patients Treated With High-Dose Interleukin-2 for Metastatic Melanoma or Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 1169-1177.                                                            | 0.8  | 330       |
| 12 | Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma. <i>JAMA Oncology</i> , 2018, 4, e180077.                                                                                                                | 3.4  | 304       |
| 13 | Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after 1-year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. , 2018, 6, 7.                                                                                 |      | 263       |
| 14 | Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma. , 2019, 7, 145.                                                                         |      | 261       |
| 15 | Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial. <i>Annals of Surgical Oncology</i> , 2016, 23, 4169-4177.                                                                   | 0.7  | 236       |
| 16 | Phase II Randomized Study of Vaccine Treatment of Advanced Prostate Cancer (E7897): A Trial of the Eastern Cooperative Oncology Group. <i>Journal of Clinical Oncology</i> , 2004, 22, 2122-2132.                                                                        | 0.8  | 226       |
| 17 | Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 1048-1054.                                                                                                        | 3.2  | 226       |
| 18 | Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma. <i>American Journal of Clinical Dermatology</i> , 2017, 18, 1-15.                                                                                                            | 3.3  | 215       |

| #  | ARTICLE                                                                                                                                                                                                                                               | IF  | CITATIONS |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 19 | Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. <i>Cancer Immunology, Immunotherapy</i> , 2000, 49, 504-514.                                   | 2.0 | 195       |
| 20 | OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. <i>Future Oncology</i> , 2010, 6, 941-949.                                                                                     | 1.1 | 195       |
| 21 | Clinical landscape of oncolytic virus research in 2020. , 2020, 8, e001486.                                                                                                                                                                           |     | 191       |
| 22 | Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase III Study. <i>Clinical Cancer Research</i> , 2010, 16, 5539-5547.                                                                  | 3.2 | 184       |
| 23 | Serum Vascular Endothelial Growth Factor and Fibronectin Predict Clinical Response to High-Dose Interleukin-2 Therapy. <i>Journal of Clinical Oncology</i> , 2009, 27, 2645-2652.                                                                     | 0.8 | 167       |
| 24 | Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 1119-1128. | 3.3 | 140       |
| 25 | Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. <i>Journal of Clinical Investigation</i> , 2005, 115, 1903-1912.                                                                        | 3.9 | 126       |
| 26 | Consensus nomenclature for CD8 <sup>+</sup> T cell phenotypes in cancer. <i>Oncolmmunology</i> , 2015, 4, e998538.                                                                                                                                    | 2.1 | 119       |
| 27 | The lymphoid chemokine CCL21 costimulates naïve T cell expansion and Th1 polarization of non-regulatory CD4+ T cells. <i>Cellular Immunology</i> , 2004, 231, 75-84.                                                                                  | 1.4 | 113       |
| 28 | Combination Chemotherapy and ALVAC-CEA/B7.1 Vaccine in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 4843-4849.                                                                                             | 3.2 | 105       |
| 29 | Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer. <i>Journal of Translational Medicine</i> , 2007, 5, 60.                                                                                                                  | 1.8 | 102       |
| 30 | Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1389-1403.                                                   | 1.1 | 102       |
| 31 | MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation. <i>Science Translational Medicine</i> , 2018, 10, .                                                                                 | 5.8 | 97        |
| 32 | Results of a phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer. <i>Annals of Surgical Oncology</i> , 1996, 3, 495-500.                                                | 0.7 | 91        |
| 33 | Optimal Management of Metastatic Melanoma: Current Strategies and Future Directions. <i>American Journal of Clinical Dermatology</i> , 2013, 14, 179-194.                                                                                             | 3.3 | 89        |
| 34 | Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1533-1544.                          | 2.0 | 89        |
| 35 | Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1. , 2019, 7, 214.                                                                                                                           |     | 86        |
| 36 | Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 685-691.                                                                            | 2.0 | 83        |

| #  | ARTICLE                                                                                                                                                                                                                                                                                         | IF  | CITATIONS |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 37 | Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 7081-7093.                                 | 1.0 | 83        |
| 38 | Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma. <i>OncImmunology</i> , 2019, 8, e1591875.                                                                                                                                              | 2.1 | 78        |
| 39 | A recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA). <i>International Journal of Cancer</i> , 1991, 48, 900-907.                                                                                                                                                       | 2.3 | 73        |
| 40 | Local Delivery of Vaccinia Virus Expressing Multiple Costimulatory Molecules for the Treatment of Established Tumors. <i>Human Gene Therapy</i> , 2006, 17, 239-244.                                                                                                                            | 1.4 | 73        |
| 41 | OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, LBA9008-LBA9008. | 0.8 | 67        |
| 42 | The promise of Immuno-oncology: implications for defining the value of cancer treatment. , 2019, 7, 129.                                                                                                                                                                                        |     | 66        |
| 43 | Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. <i>Journal of Translational Medicine</i> , 2009, 7, 2.                                                                               | 1.8 | 64        |
| 44 | Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. , 2019, 7, 131.                                                                                                                                                                                 |     | 64        |
| 45 | High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1347-1357.                                                                                                                          | 1.0 | 60        |
| 46 | An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. , 2018, 6, 44.                                                                                                                            |     | 59        |
| 47 | Immune oncology, immune responsiveness and the theory of everything. , 2018, 6, 50.                                                                                                                                                                                                             |     | 58        |
| 48 | Immunotherapy for melanoma. <i>Clinics in Dermatology</i> , 2004, 22, 251-265.                                                                                                                                                                                                                  | 0.8 | 50        |
| 49 | Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma. <i>Head and Neck</i> , 2016, 38, 1752-1758.                              | 0.9 | 49        |
| 50 | Immunotherapy for Non-melanoma Skin Cancer. <i>Current Oncology Reports</i> , 2021, 23, 125.                                                                                                                                                                                                    | 1.8 | 49        |
| 51 | Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma. <i>OncImmunology</i> , 2017, 6, e1338237.                                                                                                                                                         | 2.1 | 47        |
| 52 | Immune system versus tumor: shifting the balance in favor of DCs and effective immunity. <i>Journal of Clinical Investigation</i> , 2004, 113, 664-667.                                                                                                                                         | 3.9 | 47        |
| 53 | Insertion of interleukin-2 (IL-2) and interleukin-12 (IL-12) genes into vaccinia virus results in effective anti-tumor responses without toxicity. <i>Vaccine</i> , 2002, 20, 1862-1869.                                                                                                        | 1.7 | 45        |
| 54 | Intratumoral Approaches for the Treatment of Melanoma. <i>Cancer Journal (Sudbury, Mass )</i> , 2017, 23, 40-47.                                                                                                                                                                                | 1.0 | 45        |

| #  | ARTICLE                                                                                                                                                                                                                                                           | IF  | CITATIONS |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 55 | Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3829-3838.                                                                                                      | 0.8 | 44        |
| 56 | Final data from CALM: A phase II study of Coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9030-9030.                                                                | 0.8 | 44        |
| 57 | Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIb-IV melanoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9029-9029. | 0.8 | 43        |
| 58 | Oncolytic virus therapy for cancer. <i>Oncolytic Virotherapy</i> , 2013, 2, 31.                                                                                                                                                                                   | 6.0 | 42        |
| 59 | Pox Viral Vaccine Approaches. <i>Seminars in Oncology</i> , 2005, 32, 549-555.                                                                                                                                                                                    | 0.8 | 41        |
| 60 | The tumour microenvironment and implications for cancer immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2006, 6, 671-684.                                                                                                                            | 1.4 | 39        |
| 61 | Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials. , 2017, 5, 72.                                                                                                                                       |     | 37        |
| 62 | Cancer immunotherapy trials: leading a paradigm shift in drug development. , 2016, 4, 42.                                                                                                                                                                         |     | 35        |
| 63 | MVAâ€“5T4-induced immune responses are an early marker of efficacy in renal cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 829-837.                                                                                                         | 2.0 | 34        |
| 64 | Immunotherapy for Merkel cell carcinoma: a turning point in patient care. , 2018, 6, 23.                                                                                                                                                                          |     | 34        |
| 65 | Inhibition of p70 S6 Kinase (S6K1) Activity by A77 1726 and Its Effect on Cell Proliferation and Cell Cycle Progress. <i>Neoplasia</i> , 2014, 16, 824-834.                                                                                                       | 2.3 | 32        |
| 66 | TroVax, a recombinant modified vaccinia Ankara virus encoding 5T4: Lessons learned and future development. <i>Hum Vaccin</i> , 2010, 6, 784-791.                                                                                                                  | 2.4 | 31        |
| 67 | IFN-Î» cancer immunotherapy: new kid on the block. <i>Immunotherapy</i> , 2016, 8, 877-888.                                                                                                                                                                       | 1.0 | 30        |
| 68 | Vaccines for Melanoma and Renal Cell Carcinoma. <i>Seminars in Oncology</i> , 2012, 39, 263-275.                                                                                                                                                                  | 0.8 | 29        |
| 69 | Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 2245-2261.         | 1.2 | 28        |
| 70 | Two roads for oncolytic immunotherapy development. , 2019, 7, 26.                                                                                                                                                                                                 |     | 28        |
| 71 | Cytokine Therapy for Cancer. <i>Surgical Oncology Clinics of North America</i> , 2007, 16, 793-818.                                                                                                                                                               | 0.6 | 26        |
| 72 | Management of Metastatic Melanoma in 2018. <i>JAMA Oncology</i> , 2018, 4, 857.                                                                                                                                                                                   | 3.4 | 26        |

| #  | ARTICLE                                                                                                                                                                                                                                                                                         | IF   | CITATIONS |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 73 | Local delivery of recombinant vaccinia virus expressing secondary lymphoid chemokine (SLC) results in a CD4 T-cell dependent antitumor response. <i>Vaccine</i> , 2004, 22, 2894-2903.                                                                                                          | 1.7  | 24        |
| 74 | An Update on the Role of Talimogene Laherparepvec (T-VEC) in the Treatment of Melanoma: Best Practices and Future Directions. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 821-832.                                                                                              | 3.3  | 24        |
| 75 | Immunotherapy for Nonmelanoma Skin Cancer: Facts and Hopes. <i>Clinical Cancer Research</i> , 2022, 28, 2211-2220.                                                                                                                                                                              | 3.2  | 23        |
| 76 | Talimogene Laherparepvec: Moving From First-In-Class to Best-In-Class. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 834841.                                                                                                                                                             | 1.6  | 23        |
| 77 | Leiomyoma of the breast. , 1996, 62, 62-64.                                                                                                                                                                                                                                                     |      | 22        |
| 78 | Non-oncogenic Acute Viral Infections Disrupt Anti-cancer Responses and Lead to Accelerated Cancer-Specific Host Death. <i>Cell Reports</i> , 2016, 17, 957-965.                                                                                                                                 | 2.9  | 22        |
| 79 | Nonprogression with avelumab treatment associated with gains in quality of life in metastatic Merkel cell carcinoma. <i>Future Oncology</i> , 2018, 14, 255-266.                                                                                                                                | 1.1  | 22        |
| 80 | Unleashing the therapeutic potential of oncolytic viruses. <i>Journal of Clinical Investigation</i> , 2018, 128, 1258-1260.                                                                                                                                                                     | 3.9  | 22        |
| 81 | OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, LBA9008-LBA9008. | 0.8  | 21        |
| 82 | Immunotherapy for pancreatic cancer: current concepts. <i>Hematology/Oncology Clinics of North America</i> , 2002, 16, 159-197.                                                                                                                                                                 | 0.9  | 20        |
| 83 | Critical analysis of an oncolytic herpesvirus encoding granulocyte-macrophage colony stimulating factor for the treatment of malignant melanoma. <i>Oncolytic Virotherapy</i> , 2014, 3, 11.                                                                                                    | 6.0  | 19        |
| 84 | Chronic granulomatous dermatitis induced by talimogene laherparepvec therapy of melanoma metastases. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 48-53.                                                                                                                                   | 0.7  | 19        |
| 85 | Advancing oncolytic virus therapy by understanding the biology. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 197-198.                                                                                                                                                                    | 12.5 | 19        |
| 86 | Strategies for cancer therapy using carcinoembryonic antigen vaccines. <i>Expert Reviews in Molecular Medicine</i> , 2000, 2, 1-24.                                                                                                                                                             | 1.6  | 18        |
| 87 | Prostate-specific antigen vaccines for prostate cancer. <i>Expert Opinion on Biological Therapy</i> , 2002, 2, 395-408.                                                                                                                                                                         | 1.4  | 17        |
| 88 | CALM study: A phase II study of an intratumorally delivered oncolytic immunotherapeutic agent, coxsackievirus A21, in patients with stage IIIC and stage IV malignant melanoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3031-3031.                                                     | 0.8  | 17        |
| 89 | Surgical treatment of stage IV melanoma. <i>Clinics in Dermatology</i> , 2004, 22, 240-250.                                                                                                                                                                                                     | 0.8  | 15        |
| 90 | Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee. , 2020, 8, e001583.                                                                                                      |      | 15        |

| #   | ARTICLE                                                                                                                                                                                               | IF  | CITATIONS |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 91  | Real-world assessment of response to anti-programmed cell death 1 therapy in advanced cutaneous squamous cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 1038-1040. | 0.6 | 15        |
| 92  | TroVax <sup>®</sup> vaccine therapy for renal cell carcinoma. <i>Immunotherapy</i> , 2012, 4, 27-42.                                                                                                  | 1.0 | 14        |
| 93  | Results of a Randomized Phase I Gene Therapy Clinical Trial of Nononcolytic Fowlpox Viruses Encoding T Cell Costimulatory Molecules. <i>Human Gene Therapy</i> , 2014, 25, 452-460.                   | 1.4 | 14        |
| 94  | Surgical Management of Melanoma. <i>Cancer Treatment and Research</i> , 2016, 167, 149-179.                                                                                                           | 0.2 | 14        |
| 95  | Current Issues in Cancer Vaccine Development. <i>Clinical Immunology</i> , 1999, 92, 211-223.                                                                                                         | 1.4 | 12        |
| 96  | Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017,) Tj ETQq0 0 0 rgBT /Overlock                                                                       |     | 12        |
| 97  | Viral Vaccines for Cancer Immunotherapy. <i>Hematology/Oncology Clinics of North America</i> , 2006, 20, 661-687.                                                                                     | 0.9 | 11        |
| 98  | Avelumab and other recent advances in Merkel cell carcinoma. <i>Future Oncology</i> , 2017, 13, 2771-2783.                                                                                            | 1.1 | 11        |
| 99  | The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st Anniversary Annual Meeting. , 2017, 5, .                                                                |     | 11        |
| 100 | Can Biomarkers Guide Oncolytic Virus Immunotherapy?. <i>Clinical Cancer Research</i> , 2021, 27, 3278-3279.                                                                                           | 3.2 | 11        |
| 101 | Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9019-9019.                                                        | 0.8 | 11        |
| 102 | Clinical Perineural Invasion and Immunotherapy for Head and Neck Cutaneous Squamous Cell Carcinoma. <i>Laryngoscope</i> , 2021, , .                                                                   | 1.1 | 11        |
| 103 | COMBINATION INTERLEUKIN-2 AND INTERLEUKIN-12 INDUCES SEVERE GASTROINTESTINAL TOXICITY AND EPITHELIAL CELL APOPTOSIS IN MICE. <i>Cytokine</i> , 2002, 17, 43-52.                                       | 1.4 | 10        |
| 104 | The role of poxviruses in tumor immunotherapy. <i>Surgery</i> , 2003, 134, 731-737.                                                                                                                   | 1.0 | 10        |
| 105 | Long-Term Progression-Free Survival of Patients with Metastatic Melanoma or Renal Cell Carcinoma following High-Dose Interleukin-2. <i>Journal of Investigative Medicine</i> , 2021, 69, 888-892.     | 0.7 | 10        |
| 106 | High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma. <i>Frontiers in Oncology</i> , 2019, 9, 1483.                                                                   | 1.3 | 10        |
| 107 | Clinical features of acute kidney injury in patients receiving dabrafenib and trametinib. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 507-514.                                             | 0.4 | 10        |
| 108 | Small bowel obstruction by jejunal enterolith. <i>Surgery</i> , 1997, 121, 229-230.                                                                                                                   | 1.0 | 9         |

| #   | ARTICLE                                                                                                                                                                                                                                     | IF  | CITATIONS |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 109 | Low-dose interleukin-2 impairs host anti-tumor immunity and inhibits therapeutic responses in a mouse model of melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 9-16.                                                          | 2.0 | 9         |
| 110 | Oncolytic Immunotherapy. <i>Surgical Oncology Clinics of North America</i> , 2019, 28, 419-430.                                                                                                                                             | 0.6 | 8         |
| 111 | Abstract CT139: Intratumoral oncolytic virus V937 in combination with pembrolizumab (pembro) in patients (pts) with advanced melanoma: Updated results from the phase 1b CAPRA study. <i>Cancer Research</i> , 2021, 81, CT139-CT139.       | 0.4 | 8         |
| 112 | Multi-parametric flow cytometry staining procedure for analyzing tumor-infiltrating immune cells following oncolytic herpes simplex virus immunotherapy in intracranial glioblastoma. <i>Journal of Biological Methods</i> , 2019, 6, e112. | 1.0 | 8         |
| 113 | CALM study: A phase II study of intratumoral coxsackievirus A21 in patients with stage IIIc and stage IV malignant melanoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS3128-TPS3128.                                              | 0.8 | 7         |
| 114 | Chemokines and Cancer. <i>Cancer Investigation</i> , 2002, 20, 825-834.                                                                                                                                                                     | 0.6 | 6         |
| 115 | Manipulating the Local Tumor Microenvironment with Poxviruses Expressing Costimulatory Molecules. <i>Annals of the New York Academy of Sciences</i> , 2005, 1062, 41-50.                                                                    | 1.8 | 6         |
| 116 | Melanoma as a model for precision medicine in oncology. <i>Lancet Oncology</i> , The, 2014, 15, 251-253.                                                                                                                                    | 5.1 | 6         |
| 117 | Rational Combination Immunotherapy: Understand the Biology. <i>Cancer Immunology Research</i> , 2017, 5, 355-356.                                                                                                                           | 1.6 | 5         |
| 118 | Panniculitis after vaccination against CEA and MUC1 in a patient with pancreatic cancer. <i>Lancet Oncology</i> , The, 2005, 6, 62-3.                                                                                                       | 5.1 | 5         |
| 119 | 422â€¦An open-label, multicenter, phase 1/2 clinical trial of RP1, an enhanced potency oncolytic HSV, combined with nivolumab: updated results from the skin cancer cohorts. , 2020, , .                                                    |     | 5         |
| 120 | Innovations and strategies for the development of anticancer vaccines. <i>Expert Opinion on Pharmacotherapy</i> , 2000, 1, 603-614.                                                                                                         | 0.9 | 4         |
| 121 | Generation and validation of recombinant herpes simplex type 1 viruses (HSV-1) using CRISPR/Cas9 genetic disruption. <i>Methods in Enzymology</i> , 2020, 635, 167-184.                                                                     | 0.4 | 4         |
| 122 | Gene Therapy for Antitumor Vaccination. <i>Methods in Molecular Biology</i> , 2009, 542, 515-527.                                                                                                                                           | 0.4 | 4         |
| 123 | High-dose (HD) IL-2 for metastatic renal cell carcinoma (mRCC) in the targeted therapy era: Extension of OS benefits beyond complete response (CR) and partial response (PR).. <i>Journal of Clinical Oncology</i> , 2014, 32, 4523-4523.   | 0.8 | 4         |
| 124 | Combination Immunotherapy for Melanoma. <i>JAMA Oncology</i> , 2015, 1, 387.                                                                                                                                                                | 3.4 | 3         |
| 125 | Avelumab Immunotherapy: Management of Adverse Events Associated With New Treatment for Merkel Cell Carcinoma. , 2019, 23, E1-E9.                                                                                                            |     | 3         |
| 126 | Defining current gaps in quality measures for cancer immunotherapy: consensus report from the Society for Immunotherapy of Cancer (SITC) 2019 Quality Summit. , 2020, 8, e000112.                                                           |     | 3         |



| #   | ARTICLE                                                                                                                                                                                                                                                                                                       | IF  | CITATIONS |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 127 | Diagnostic yield of staging brain magnetic resonance imaging is low in Merkel cell carcinoma: A single-institution cohort study. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 434-435.                                                                                                   | 0.6 | 3         |
| 128 | Safety and efficacy of ipilimumab in melanoma patients who received prior immunotherapy on phase III study MDX010-020.. <i>Journal of Clinical Oncology</i> , 2013, 31, 9050-9050.                                                                                                                            | 0.8 | 3         |
| 129 | Improved median overall survival (OS) in patients with metastatic melanoma (mM) treated with high-dose (HD) IL-2: Analysis of the PROCLAIM 2007-2012 national registry.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9054-9054.                                                                           | 0.8 | 3         |
| 130 | High dose (HD) IL-2 for metastatic renal cell carcinoma (mRCC) in the targeted therapy era: Extension of OS benefits beyond complete response (CR) and partial response (PR).. <i>Journal of Clinical Oncology</i> , 2015, 33, 423-423.                                                                       | 0.8 | 3         |
| 131 | 421â€œ..Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors. , 2020, , .                                                                                  |     | 3         |
| 132 | An update on TroVax&reg; for the treatment of progressive castration-resistant prostate cancer. <i>OncoTargets and Therapy</i> , 2011, 4, 33.                                                                                                                                                                 | 1.0 | 2         |
| 133 | Introduction on Cancer Immunology and Immunotherapy. , 2015, , 1-8.                                                                                                                                                                                                                                           |     | 2         |
| 134 | OPTiM: A randomized phase III trial to evaluate the efficacy and safety of talimogene laherparepvec (T-VEC) compared with subcutaneously (sc) administered GM-CSF for the treatment (tx) of unresectable stage IIIb, IIIc, and IV melanoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS8604-TPS8604. | 0.8 | 2         |
| 135 | High-dose interleukin-2 registry, PROCLAIM: Modern data on toxicities and outcomes.. <i>Journal of Clinical Oncology</i> , 2014, 32, 430-430.                                                                                                                                                                 | 0.8 | 2         |
| 136 | Dynamics of tumor response in advanced melanoma patients treated with Cocksackievirus A21.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9553-9553.                                                                                                                                                        | 0.8 | 2         |
| 137 | A Prospective Analysis of High-Dose Interleukin-2 (HD IL-2) following PD-1 inhibitor therapy in patients with metastatic melanoma and renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, e21006-e21006.                                                                                   | 0.8 | 2         |
| 138 | TNFâ€œ+â€œinduced activation of RhoA/Rho kinase pathway in human pulmonary microvascular endothelial cells. <i>FASEB Journal</i> , 2007, 21, A1201.                                                                                                                                                           | 0.2 | 2         |
| 139 | Synthetic biology: at the crossroads of genetic engineering and human therapeuticsâ€œ”a Keystone Symposia report. <i>Annals of the New York Academy of Sciences</i> , 2021, , .                                                                                                                               | 1.8 | 2         |
| 140 | Cytokines in the Treatment of Cancer. , 2013, , 173-210.                                                                                                                                                                                                                                                      |     | 1         |
| 141 | Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade. <i>OncImmunology</i> , 2019, 8, e1571390.                                                                                                                                                 | 2.1 | 1         |
| 142 | Durability of responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2 (HD IL-2).. <i>Journal of Clinical Oncology</i> , 2016, 34, 511-511.                                                                                                                            | 0.8 | 1         |
| 143 | Overall survival (OS) by clinical risk category for high dose interleukin-2 (HD IL-2) treated metastatic renal cell cancer (RCC): Data from PROCLAIM.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4578-4578.                                                                                             | 0.8 | 1         |
| 144 | Columbia University. <i>Lancet Oncology</i> , The, 2005, 6, 750.                                                                                                                                                                                                                                              | 5.1 | 0         |

| #   | ARTICLE                                                                                                                                                                                                                                      | IF  | CITATIONS |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 145 | DNA Vaccines for Cancer Immunotherapy. , 2006, , 87-114.                                                                                                                                                                                     |     | 0         |
| 146 | Modified Oncolytic Herpesviruses for Gene Therapy of Cancer. , 2014, , 213-223.                                                                                                                                                              |     | 0         |
| 147 | Finding gold in tumour immunotherapy. Lancet Oncology, The, 2017, 18, e561.                                                                                                                                                                  | 5.1 | 0         |
| 148 | Can Surgeons Expand the Role of Oncolytic Viruses for Cancer Treatment? An Editorial Comment on "Fighting Fire with Fire: Oncolytic Virotherapy in Thoracic Malignancies". Annals of Surgical Oncology, 2021, 28, 2432-2433.                 | 0.7 | 0         |
| 149 | DNA Vaccines. , 2004, , 225-248.                                                                                                                                                                                                             |     | 0         |
| 150 | Modulating the Tumor Microenvironment. , 2012, , 353-369.                                                                                                                                                                                    |     | 0         |
| 151 | Effect of the novel therapeutic cancer vaccine formulation DPX-0907 on multifunctional T-cell responses in ovarian, breast, and prostate cancer patients.. Journal of Clinical Oncology, 2012, 30, 2588-2588.                                | 0.8 | 0         |
| 152 | Interleukin 2. , 2013, , 1-12.                                                                                                                                                                                                               |     | 0         |
| 153 | CTLA-4. , 2013, , 1-14.                                                                                                                                                                                                                      |     | 0         |
| 154 | An exploratory study of the biologic effects of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) treatment in patients (pts) with advanced (unresectable or metastatic) melanoma (MEL).. Journal of Clinical Oncology, 2013, 31, TPS3114-TPS3114. | 0.8 | 0         |
| 155 | The Use of Oncolytic Herpesvirus for the Treatment of Cancer. , 2014, , 329-345.                                                                                                                                                             |     | 0         |
| 156 | A Phase II multicenter trial to evaluate combination ipilimumab and high-dose IL-2 in patients with unresectable stage III and IV melanoma.. Journal of Clinical Oncology, 2015, 33, TPS3095-TPS3095.                                        | 0.8 | 0         |
| 157 | Interleukin-12. , 2016, , 1-15.                                                                                                                                                                                                              |     | 0         |
| 158 | High Dose Interleukin-2 Therapy. , 2007, , 431-452.                                                                                                                                                                                          |     | 0         |
| 159 | Combination Cytokine Therapy. , 2007, , 373-398.                                                                                                                                                                                             |     | 0         |